Patent Issued for Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase (USPTO 12121567).

MLA

“Patent Issued for Methods to Treat Mucopolysaccharidosis Type II or Deficiency in Iduronate-2-Sulfatase Using a Recombinant Adeno-Associated Virus (AAV) Vector Encoding Iduronate-2-Sulfatase (USPTO 12121567).” Gene Therapy Weekly, Nov. 2024, p. 2335. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=180747643&authtype=sso&custid=ns315887.

APA

Patent Issued for Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase (USPTO 12121567). (2024). Gene Therapy Weekly, 2335.

Chicago

“Patent Issued for Methods to Treat Mucopolysaccharidosis Type II or Deficiency in Iduronate-2-Sulfatase Using a Recombinant Adeno-Associated Virus (AAV) Vector Encoding Iduronate-2-Sulfatase (USPTO 12121567).” 2024. Gene Therapy Weekly, November, 2335. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=180747643&authtype=sso&custid=ns315887.